{
    "claims": [
        {
            "claim_id": "C01",
            "claim": "Intratumoral mRNA vaccination enhances the display of tumor antigens.",
            "strength": "strong",
            "evidence": [
                {
                    "quote": "Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3%",
                    "line_ref": "L28"
                },
                {
                    "quote": "Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6%",
                    "line_ref": "L29"
                }
            ],
            "caveat": "The observed broadening of the immunopeptidome was demonstrated in murine models and may not be representative of all tumor types or human responses."
        },
        {
            "claim_id": "C02",
            "claim": "mRNA vaccination induces a type I interferon response in tumors, which is crucial for the sensitization effect.",
            "strength": "strong",
            "evidence": [
                {
                    "quote": "Type I interferon response score (normalized units) | 3.1 | 1.0",
                    "line_ref": "L31"
                },
                {
                    "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
                    "line_ref": "L39"
                }
            ],
            "caveat": "The level of interferon induction and its downstream effects can be highly variable depending on the tumor microenvironment and the specific mRNA construct used."
        },
        {
            "claim_id": "C03",
            "claim": "The combination of mRNA vaccination and anti-PD-L1 therapy leads to increased T-cell infiltration and better tumor control in mice.",
            "strength": "moderate",
            "evidence": [
                {
                    "quote": "Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x",
                    "line_ref": "L33"
                },
                {
                    "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
                    "line_ref": "L46"
                }
            ],
            "caveat": "This effect was observed in specific mouse models and may not generalize to all cancer types. The contribution of each component (vaccine, ICI) to the overall outcome can be difficult to disentangle."
        },
        {
            "claim_id": "C04",
            "claim": "Prior SARS-CoV-2 mRNA vaccination is associated with improved survival in metastatic patients receiving ICI treatment.",
            "strength": "tentative",
            "evidence": [
                {
                    "quote": "Retrospective human survival comparison p-value | p=0.01 | N/A",
                    "line_ref": "L30"
                },
                {
                    "quote": "The human analysis is retrospective and non-randomized; residual confounding is likely.",
                    "line_ref": "L49"
                }
            ],
            "caveat": "This is a retrospective, non-randomized study with a high risk of confounding variables. A causal relationship cannot be established without prospective, randomized clinical trials."
        }
    ]
}